📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-01 17:08
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
7 announcements match the current filters (relevance ≥ 5).
Vaxfab Enterprises approves rights issue to raise up to Rs 45 crore
Vaxfab Enterprises has approved raising funds up to Rs 45.00 crore through a rights issue of equity shares of face value Rs 10 each. The proposed fundraise represents approximately 94% of the company's net worth (Rs 48 crore) and 4.5% of its market capitalization (Rs 995 crore). The board also approved the Draft Letter of Offer to be filed with BSE Limited and constituted a Rights Issue Committee. Issue price, rights entitlement ratio, and record date will be determined subsequently.
Confidence: HIGH
What changedThe board approved a capital raise of up to Rs 45 crore via a rights issue and authorized the filing of the Draft Letter of Offer.
Why it mattersThe Rs 45 crore raise is substantial relative to the company's net worth of Rs 48 crore, which could dilute equity or bolster working capital amid recent quarterly operating losses.
Maximum fundraise amount: Rs 45,00,00,000Face value per share: Rs 10.00Fundraise vs Net Worth: ~93.8%Fundraise vs Market Cap: ~4.5%
📅 Short termMarket attention will focus on the pricing of the rights issue relative to the current market price of Rs 64.2 and the dilution ratio.
📈 Long termThe infusion could help support operations and balance sheet liquidity given the recent losses, though long-term value will depend on capital deployment efficiency.
⚠ Risk flags
- Equity dilution risk for non-participating shareholders
- Issue terms including price and ratio are yet to be finalized
Key Highlights
Rights issue approved for an aggregate amount of up to Rs 45,00,00,000 (Rs 45 crore)
Proposed securities are equity shares with a face value of Rs 10.00 each
Draft Letter of Offer approved for filing with BSE Limited
Rights Issue Committee formed comprising 3 members under Chairman Ravindra Ashokbhai Joshi
👀 What to Watch
Track the filing of the Draft Letter of Offer with BSE and subsequent announcements regarding the rights entitlement ratio, issue price, and record date.
Vaxfab Enterprises approves rights issue to raise up to Rs 45 crore
Vaxfab Enterprises has approved raising funds up to Rs 45.00 crore through a rights issue of equity shares of face value Rs 10 each. The proposed fundraise represents approximately 94% of the company's net worth (Rs 48 crore) and 4.5% of its market capitalization (Rs 995 crore). The board also approved the Draft Letter of Offer to be filed with BSE Limited and constituted a Rights Issue Committee. Issue price, rights entitlement ratio, and record date will be determined subsequently.
Confidence: HIGH
What changedThe board approved a capital raise of up to Rs 45 crore via a rights issue and authorized the filing of the Draft Letter of Offer.
Why it mattersThe Rs 45 crore raise is substantial relative to the company's net worth of Rs 48 crore, which could dilute equity or bolster working capital amid recent quarterly operating losses.
Maximum fundraise amount: Rs 45,00,00,000Face value per share: Rs 10.00Fundraise vs Net Worth: ~93.8%Fundraise vs Market Cap: ~4.5%
📅 Short termMarket attention will focus on the pricing of the rights issue relative to the current market price of Rs 64.2 and the dilution ratio.
📈 Long termThe infusion could help support operations and balance sheet liquidity given the recent losses, though long-term value will depend on capital deployment efficiency.
⚠ Risk flags
- Equity dilution risk for non-participating shareholders
- Issue terms including price and ratio are yet to be finalized
Key Highlights
Rights issue approved for an aggregate amount of up to Rs 45,00,00,000 (Rs 45 crore)
Proposed securities are equity shares with a face value of Rs 10.00 each
Draft Letter of Offer approved for filing with BSE Limited
Rights Issue Committee formed comprising 3 members under Chairman Ravindra Ashokbhai Joshi
👀 What to Watch
Track the filing of the Draft Letter of Offer with BSE and subsequent announcements regarding the rights entitlement ratio, issue price, and record date.
Vaxfab Enterprises Allots 8.26 Lakh Shares at Rs 21.02 on Warrant Conversion
Vaxfab Enterprises has approved the allotment of 8,26,761 equity shares of face value Rs 10 each upon conversion of warrants on a preferential basis to 9 investors. The shares were allotted at an issue price of Rs 21.02 each, bringing in the remaining conversion consideration of Rs 15.765 per warrant (aggregating to ~Rs 1.30 crore). Following this allotment, the company's paid-up equity capital increased to Rs 25.83 crore across 2,58,26,406 equity shares. The newly allotted shares rank pari-passu with existing equity shares.
Confidence: HIGH
What changedConversion of 8,26,761 outstanding warrants into fully paid-up equity shares, expanding the equity base to 2.58 crore shares.
Why it mattersInfuses ~Rs 1.30 crore in cash from the balance warrant consideration, with a minor ~3.2% equity dilution.
Shares Allotted: 8,26,761Issue Price per Share: Rs 21.02Conversion Price Received per Warrant: Rs 15.765Post-Allotment Paid-Up Capital: Rs 25,82,64,060Post-Allotment Total Shares: 2,58,26,406
📅 Short termNeutral; minor supply increase once the 8.26 lakh converted shares are credited and granted trading permissions.
📈 Long termLimited structural impact given the relatively small size of the capital infusion.
⚠ Risk flags
- Equity dilution from warrant exercise
- Warrant conversion price of Rs 21.02 is at a steep discount to the current market price of Rs 65.3
Key Highlights
Allotted 8,26,761 equity shares of Rs 10 face value upon warrant conversion to 9 investors
Conversion price received was Rs 15.765 per warrant against total issue price of Rs 21.02 per share
Paid-up equity share capital expanded to Rs 25,82,64,060 comprising 2,58,26,406 equity shares
Results in ~3.2% dilution of the post-allotment equity base
👀 What to Watch
Track receipt of listing and trading approvals for the newly allotted shares on the stock exchange.
Vaxfab Enterprises Allots 8.26 Lakh Shares on Warrant Conversion at Rs 21.02/Share
Vaxfab Enterprises Limited has approved the allotment of 8,26,761 equity shares of face value Rs 10 each at an issue price of Rs 21.02 per share upon the conversion of preferential warrants. The company received the balance exercise amount of Rs 15.765 per warrant from 9 investors, generating approximately Rs 1.30 crore in cash. Following this allotment, the paid-up share capital increases to Rs 25.83 crore divided into 2,58,26,406 equity shares.
Confidence: HIGH
What changedVaxfab Enterprises converted 8,26,761 preferential warrants into fully paid-up equity shares, expanding its equity base to 2.58 crore shares.
Why it mattersBrings in ~Rs 1.30 crore in incremental cash proceeds at the cost of ~3.20% equity dilution.
Shares allotted: 8,26,761Issue price: Rs 21.02Conversion price received: Rs 15.765 per warrantPost-allotment share capital: Rs 25,82,64,060Post-allotment total shares: 2,58,26,406Equity dilution: ~3.20%
📅 Short termThe newly allotted shares will soon be eligible for trading, which may introduce moderate supply given the conversion price of Rs 21.02 is below the current market price.
📈 Long termLimited; this is a procedural execution of previously approved preferential warrants with minor impact on overall balance sheet size.
⚠ Risk flags
- Equity dilution of ~3.20%
- Warrant conversion price (Rs 21.02) is at a steep discount to recent market price (Rs 65.3)
Key Highlights
Allotment of 8,26,761 equity shares of face value Rs 10 at Rs 21.02 per share upon warrant conversion
Received balance exercise price of Rs 15.765 per warrant across 9 investors (~Rs 1.30 crore)
Post-allotment paid-up share capital increased to Rs 25,82,64,060 comprising 2,58,26,406 equity shares
Dilution from this allotment represents approximately 3.20% of the expanded share capital
👀 What to Watch
Track listing and trading approvals for the newly allotted 8.26 lakh equity shares on BSE and Calcutta Stock Exchange.
Vaxfab Enterprises Reports Q1 Standalone Net Loss of ₹5.84 Cr; Revenue Drops to ₹0.40 Cr
Vaxfab Enterprises reported a sharp decline in financial performance for the quarter ended June 30, 2026. Standalone revenue from operations slumped to ₹0.40 Cr (₹40.00 Lakhs) compared to ₹14.57 Cr in Q1 FY26. Standalone net loss stood at ₹5.84 Cr versus a net profit of ₹0.39 Cr in the year-ago period, heavily impacted by notional losses on fair valuation of investments. On a consolidated basis, revenue stood at ₹0.40 Cr with a net loss attributable to owners of ₹3.04 Cr.
Confidence: HIGH
What changedThe company swung into a deep net loss of ₹5.84 Cr in Q1 FY27 alongside a near-total collapse in core operational revenue to ₹0.40 Cr.
Why it mattersThe steep revenue drop and non-operational investment valuation losses undermine profitability predictability and operational stability.
Standalone Revenue from Operations (Q1): ₹40.00 LakhsStandalone Net Loss (Q1): ₹584.09 LakhsConsolidated Net Loss (Q1): ₹303.65 LakhsStandalone Diluted EPS: ₹(2.31)Paid-up Equity Capital: ₹2525.96 Lakhs
📅 Short termLikely negative sentiment following severe revenue contraction and large mark-to-market investment losses.
📈 Long termLimited visibility until the core trading operations demonstrate steady revenue flow and reduced reliance on volatile financial asset valuations.
⚠ Risk flags
- Severe drop in operational revenue
- High earnings volatility due to fair value mark-to-market adjustments on investments
- Substantial equity dilution indicated by paid-up capital expansion
Key Highlights
Standalone revenue from operations fell sharply to ₹0.40 Cr (₹40.00 Lakhs) from ₹14.57 Cr in Q1 FY26
Standalone net loss widened to ₹5.84 Cr (₹584.09 Lakhs) compared to a net profit of ₹0.39 Cr in Q1 FY26
Consolidated net loss attributable to owners stood at ₹3.04 Cr (₹303.65 Lakhs)
Management attributed the loss primarily to a notional loss on fair valuation of investments under Ind AS 109
Paid-up equity share capital increased to ₹25.26 Cr (₹2525.96 Lakhs) from ₹8.40 Cr
👀 What to Watch
Track core operational trading revenue recovery in upcoming quarters and monitor any disclosures regarding investment portfolio holdings driving fair-value mark-to-market swings.
Vaxfab Q1 Standalone Loss at ₹5.84 Cr as Revenue Drops 97% YoY to ₹0.40 Cr
Vaxfab Enterprises reported a standalone net loss of ₹5.84 crore for Q1 ended June 30, 2026, compared to a net profit of ₹0.39 crore in the same period last year and ₹5.02 crore in the preceding quarter. Standalone revenue from operations dropped 97.3% YoY to ₹0.40 crore from ₹14.57 crore in Q1 FY26. Management noted the loss was primarily driven by notional mark-to-market losses on fair valuation of investments under Ind AS 109, which pushed standalone other expenses to ₹5.84 crore. On a consolidated basis, net loss attributable to owners came in at ₹3.04 crore, while paid-up equity share capital increased to ₹25.26 crore from ₹8.40 crore.
Confidence: HIGH
What changedVaxfab posted a net loss of ₹5.84 crore amid a severe 97% drop in quarterly top-line and marked an expansion in equity share capital.
Why it mattersA sharp deceleration in core trading operations combined with investment fair-value losses significantly strains earnings visibility and margin stability.
Standalone Revenue (Q1): 40.00 LacsStandalone Net Profit/Loss (Q1): (584.09) LacsConsolidated Net Loss (Q1): (303.65) LacsPaid-up Equity Capital: 2525.96 LacsQ1 Standalone Revenue vs TTM Revenue: ~0.43%
📅 Short termNegative sentiment is likely given the steep drop in operational revenue and sharp swing into substantial net losses.
📈 Long termStructural recovery hinges on stabilizing core trading turnover and reducing volatility from fair-value investment accounting.
⚠ Risk flags
- Severe operational revenue decline to ₹0.40 crore
- Earnings vulnerability to notional investment fair valuation losses
- Substantial equity dilution as share capital rose to ₹25.26 crore
Key Highlights
Standalone revenue from operations fell 97.3% YoY to ₹0.40 crore (40.00 lakhs) from ₹14.57 crore in Q1 FY26
Standalone net loss stood at ₹5.84 crore (584.09 lakhs) vs a net profit of ₹0.39 crore in Q1 FY26
Loss primarily driven by notional fair valuation loss on investments, pushing other expenses to ₹5.84 crore
Paid-up equity share capital expanded sharply to ₹25.26 crore (2525.96 lakhs) from ₹8.40 crore
👀 What to Watch
Track whether trading volumes recover in subsequent quarters and look for disclosures regarding equity capital dilution and investment portfolio details.
Vaxfab Enterprises incorporates 100% UAE subsidiary Al Rafa Enterprise FZ-LLC
Vaxfab Enterprises has incorporated a wholly-owned subsidiary (WOS) in the UAE named Al Rafa Enterprise FZ-LLC on August 6, 2026. The subsidiary is based in the Ras Al Khaimah Economic Zone and will engage in diverse activities including seeds trading, packaging materials, and IT consultancy. The initial capital is being paid in cash at AED 1,000 per share, though the total investment amount was not disclosed. This move marks an international expansion for the company, which reported a FY26 revenue of Rs 94.11 Cr and a net profit of Rs 3.64 Cr.
Confidence: HIGH
What changedThe company has established a new wholly-owned international subsidiary in the UAE to diversify its trading and consulting operations.
Why it mattersThis expansion allows Vaxfab to tap into international markets and benefit from the UAE's trading infrastructure, potentially scaling its TTM revenue of Rs 94 Cr.
Ownership acquired: 100%Cost per share: AED 1,000.00Incorporation Date: August 6, 2026TTM Revenue: Rs 94 CrNet Worth: Rs 48 Cr
📅 Short termNeutral to slightly positive as the market recognizes the intent for international expansion; however, no immediate financial impact is expected until operations commence.
📈 Long termStructural positive if the company successfully leverages the UAE hub to grow its trading volumes, though execution in a new geography is a key variable.
⚠ Risk flags
- Execution risk in a foreign jurisdiction
- Broad business scope may lead to lack of operational focus
- Total initial capital outlay not specified
Key Highlights
100% ownership established in the new UAE-based entity Al Rafa Enterprise FZ-LLC
Incorporation completed on August 6, 2026, under the Ras Al Khaimah Economic Zone Authority
Initial share price for the subsidiary set at AED 1,000.00 per share
Business mandate covers 5+ sectors including Seeds Trading, IT Consulting, and General Trading
Company reported TTM revenue of Rs 94 Cr and Net Worth of Rs 48 Cr prior to this expansion
👀 What to Watch
Monitor future quarterly results for the commencement of operations and the subsidiary's contribution to consolidated revenue and margins.
